Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

U101

Phase 3Small molecule

TTCM Biotech International Corp.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Urinary Tract Infections in WomenRecruiting

Recurrent Urinary Tract Infections in WomenPhase 3

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Recurrent Urinary Tract Infections in Women

NCT07184827

Clinical

Trials by Indication[1]

Recurrent Urinary Tract Infections in Women1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women

Recruiting·TTCM Biotech International Corp.·Phase 3·NCT07184827·348 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for U101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — U101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for U101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TCM Biotech International Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTCM Biotech International Corp.

Related News